ClinicalTrials.gg
CompletedNCT04198584VC-CBCSUpdated Oct 24, 2022Results posted

Study of Telemedicine Stress Management and Lifestyle Group Intervention for HCV Patients

An interventional study of VC-CBCS in Chronic Hepatitis C, sponsored by University of North Carolina, Chapel Hill. Completed at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2022-10-24.

Sponsored by University of North Carolina, Chapel Hill · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Study summary

A pilot feasibility study of a small randomized controlled trial (RCT) comparing a video-conferencing cognitive behavioral coping skills (VC-CBCS) group to standard of care (SC) for symptomatic patients previously diagnosed with chronic hepatitis C to evaluate feasibility, patient satisfaction and differences in symptoms, quality of life and liver markers.

Read the detailed description

This is a pilot feasibility study of a small randomized controlled trial (RCT) to evaluate a cognitive behavioral coping skills (CBCS) delivered via videoconferencing, referred to as the "VC-CBCS" compared to standard of care (SC). The study included a representative sample of 32 symptomatic patients who have/had chronic hepatitis C. Patients (n=32) were randomized in a 1:3 ratio to (1) standard of care (SC) or (2) to participate in 14, two hour VC-CBCS sessions. Four groups of patients were randomized and consisted of 7-9 patients each. The groups were as follows:

  • Group 1: 7 patients with 5 randomized to VC-CBCS and 2 to SC;
  • Group 2: 9 patients with 7 randomized to VC-CBCS and 2 to SC;
  • Groups 3 and 4: 8 patients each with 6 randomized to VC-CBCS and 2 to SC each group.

Each wave of VC-CBCS patients formed a group to join the Group Facilitator via a WebEx platform on a weekly basis using iPads from their homes. The telehealth intervention provided group-based education, skills and practices involving stress management, coping with symptoms, and support for healthy lifestyle changes. The researchers examined: (1) the feasibility of delivering a group intervention via telehealth technology remotely using iPads, (2) participant satisfaction with the intervention, and (3) whether differences are observed in several outcomes between the two conditions on quality of life, physical and mental symptoms, and liver markers. Participants completed patient-reported outcome (PRO) surveys at four time points during the study, with main outcomes being change from pre-intervention to post-intervention.

02

Conditions studied

  • Chronic Hepatitis C
03

In context

Hepatitis C, Chronic

1,090 studies on the registry are indexed under Hepatitis C, Chronic; 9 are open to participants now.

This study's enrollment of 32 is below the median of 90 across 789 interventional studies indexed under Hepatitis C, Chronic.

Browse Hepatitis C, Chronic studies →

Lead sponsor

University of North Carolina, Chapel Hill is the lead sponsor of 1,366 studies on the registry; 133 are open to participants now.

Of its 158 completed or terminated interventional studies of FDA-regulated products, 139 (88%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 21 and older;
  • Medically cleared by hepatology
  • Patients who are currently or were previously diagnosed with chronic Hepatitis C Viral (HCV) infection;
  • Evidence of ongoing symptoms, stress, or unhealthy lifestyle habits, defined as a score of greater than or equal to 4 on a scale 0(none) - 10 (severe) on two or more numeric rating scale questions (see Screening Form 1);
  • Able to read and speak English.

Exclusion criteria

Exclusion Criteria:

  • Decompensated liver disease (Childs Pugh C) judged by hepatologist or recorded in patient medical record;
  • Life expectancy of \<12 months estimated by hepatologist;
  • Has had a liver transplant or is on the wait list for a transplant
  • Severe alcohol or substance use disorder, psychiatric disorder or cognitive impairment that is likely to interfere with the ability to participate in telehealth groups and follow guidelines about group participation as judged by the Hepatology provider or research staff;
  • Lack of private, quiet space in home in which to participate in VC-CBCS sessions
  • Unwilling to have intervention sessions audio-recorded
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    VC-CBCS Intervention

    The VC-CBCS intervention was delivered via WebEx videoconferencing technology and included 14, 2-hour long sessions that involved group-based psychoeducation, cognitive and behavioral skills training, stress management, relaxation practice and healthy lifestyle habits to support overall health and liver health. Intervention materials included a hard copy Patient Workbook and audio-recorded relaxation techniques.

    Behavioral: VC-CBCS

  • No intervention
    Standard of Care (SC)

    Participants randomized to SC received no intervention and were followed by medical providers in clinic per clinical practice guidelines and clinicians discretion.

Interventions

  • BehavioralVC-CBCS

    A 14-module stress management and lifestyle group-based intervention delivered via videoconferencing WebEx technology to participants who have/had chronic hepatitis C and experience symptoms, stress or lifestyle requirements to promote liver health.

06

What researchers measure

Primary outcomes

  1. Percentage of Patients Consented Versus Approached

    One feasibility measure was to evaluate the percentage of patients consented compared to those approached for participation in the study.

    Time frame: Six Months

  2. Percentage of Participants Consented Versus Randomized

    One feasibility measure was to evaluate the percentage of participants randomized for the study compared to those consented.

    Time frame: Six Months

  3. Percentage of Standard of Care Condition Participants Retained vs Enrolled

    Percentage of standard of care condition participants retained in the study compared to those enrolled. Retention is defined as participants who submitted PRO assessments up through T4 (end of study).

    Time frame: Six Months

  4. Percentage of VC-CBCS Intervention Condition Participants Retained vs Enrolled

    Percentage of VC-CBCS Intervention participants retained in the study compared to those enrolled. Retention is defined as participants who completed at least 3 intervention sessions.

    Time frame: Six Months

  5. Percentage of Surveys Completed by Participants Who Completed the Study

    Percentage of surveys over time completed by participants who completed the study. Surveys included 12 patient-reported primary and secondary outcome measures. Completion was defined as submission of each of the 12 surveys at Time 1 (T1) through Time 4 (T4).

    Time frame: Baseline (T1) to Week 14 (T4)

  6. Global Health Status Physical Health Mean T-Score

    The Patient Reported Outcome Measurement Information System (PROMIS) Global Health Status measure is a 10-item short form that was used to measure an individual's physical, mental, and social health. Item responses range from 5 = None to 1 = Very Severe. The adult PROMIS Global Health measure produces two scores: Physical Health and Mental Health. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 16.2 to 67.7. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation better (more healthy) than the general population.

    Time frame: Baseline (T1), Week 14 (T4)

  7. Global Health Status Mental Health Mean T-Score

    The PROMIS Global Health Status measure is a 10-item short form that was used to measure an individual's physical, mental, and social health. Item responses range from 5 = None to 1 = Very Severe. The adult PROMIS Global Health measure produces two scores: Physical Health and Mental Health. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 21.2 to 67.7. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation better (more healthy) than the general population.

    Time frame: Baseline (T1), Week 14 (T4)

  8. Depression Mean T-score

    The PROMIS Depression measure is an 8-item short form that was used to measure patient-reported depression. Item responses range from 1 = Never to 5 = Always. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 41.0 to 79.4. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation more (more Depression) than the general population.

    Time frame: Baseline (T1), Week 14 (T4)

  9. Anger Mean T-score

    The PROMIS Anger measure is a 5-item short form that was used to measure patient-reported anger. Item responses range from 1 = Never to 5 = Always. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 32.9 to 82.9. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation more Anger and T-score=40 is 1 standard deviation less Anger than the general population.

    Time frame: Baseline (T1), Week 14 (T4)

  10. Anxiety Mean T-score

    The PROMIS Anxiety measure is a 4-item short form that was used to measure patient-reported anxiety. Item responses range from 1 = Never to 5 = Always. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 40.3 to 81.6. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation more Anxiety and T-score=40 is 1 standard deviation less Anxiety than the general population. The Anxiety T-score can range from 40.3 - 81.6.

    Time frame: Baseline (T1), Week 14 (T4)

  11. Fatigue Mean T-score

    The PROMIS Fatigue measure is a 7-item short form that was used to measure patient-reported fatigue. Item responses range from 1 = Never to 5 = Always. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 29.4 to 83.2. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation more Fatigue and T-score=40 is 1 standard deviation less Fatigue than the general population.

    Time frame: Baseline (T1), Week 14 (T4)

  12. Sleep Disturbance Mean T-score

    The PROMIS Sleep Disturbance measure is an 8-item short form that was used to measure patient-reported sleep disturbance. Item responses range from 1 = Never to 5 = Always. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 32.0 to 73.3. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation more Sleep Disturbance and T-score=40 is 1 standard deviation less Sleep Disturbance than the general population.

    Time frame: Baseline (T1), Week 14 (T4)

  13. Pain Interference Mean T-score

    The PROMIS Pain Interference measure is an 8-item short form that was used to measure patient-reported pain interference. Item responses range from 1 = Never to 5 = Always. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 41.6 to 75.6. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation more Pain Interference and T-score=40 is 1 standard deviation less Pain Interference than the general population.

    Time frame: Baseline (T1), Week 14 (T4)

Secondary outcomes

  1. Perceived Stress Mean Score

    The Perceived Stress Scale (PSS) is a widely used survey to measure stress perception. The scale includes 10 items, rated using a 5-point scale, from 0 (never) to 4 (very often) where patients report the frequency of stress symptoms in the past month. Items are summed with a minimum and maximum ranging from 0 to 40. Higher PSS scores reflect higher subjective stress.

    Time frame: Baseline (T1), Week 14 (T4)

  2. Coping Skills Confidence Mean Score

    The Measure of Current Status (MOCS)-Part A measured participant confidence in performing multiple skills including stress awareness, relaxation, assertiveness, and coping skills. The scale contains 13 items rated on a scale from 0 = I cannot do this at all to 4 = I can do this extremely well. A Total Coping Skills score is created by taking the average of the 13 items. The Total Coping Skill score can range from a minimum of 0 to a maximum of 4.

    Time frame: Baseline (T1), Week 14 (T4)

  3. Participant Satisfaction With VC-CBCS Intervention Mean Score

    After each VC-CBCS intervention session, participants completed a 14-item acceptability/satisfaction survey about their impressions with the current intervention session. Items are scored on a scale from 1= not at all to 5=extremely useful. Data across all VC-CBCS participants and all intervention sessions were averaged into a Total Patient Satisfaction score that could range from a minimum of 1 to a maximum of 5 with higher scores indicating greater satisfaction.

    Time frame: Baseline (T1) to Week 14 (T4)

  4. Aspartate Aminotransferase (AST) Mean Score for Females

    Liver enzyme level (AST U/L). Reference range for females is 14-38 U/L. Numbers higher than these reference ranges are considered in the abnormal range and can suggest liver damage or inflammation. These comparisons were only made for participants who had already achieved viral cure at baseline and who were not on medical treatment for chronic hepatitis C at baseline.

    Time frame: Baseline (T1), Week 14 (T4)

  5. Aspartate Aminotransferase (AST) Mean Score for Males

    Liver enzyme level (AST U/L). Reference range for males is 19-55 U/L. Numbers higher than these reference ranges are considered in the abnormal range and can suggest liver damage or inflammation. These comparisons were only made for participants who had already achieved viral cure at baseline and who were not on Hepatitis C Virus (HCV) treatment at baseline.

    Time frame: Baseline (T1), Week 14 (T4)

  6. Alanine Aminotransferase (ALT) Mean Score for Females

    Liver enzyme level (ALT U/L). Reference range for females is \<35 U/L. Numbers higher than these reference ranges are considered in the abnormal range and can suggest liver damage or inflammation. These comparisons were only made for participants who had already achieved viral cure at baseline and who were not on HCV treatment at baseline.

    Time frame: Baseline (T1), Week 14 (T4)

  7. Alanine Aminotransferase (ALT) Mean Score for Males

    Liver enzyme level (ALT U/L). Reference range for males is \<50 U/L. Numbers higher than these reference ranges are considered in the abnormal range and can suggest liver damage or inflammation. These comparisons were only made for participants who had already achieved viral cure at baseline and who were not on HCV treatment at baseline.

    Time frame: Baseline (T1), Week 14 (T4)

  8. Pittsburgh Sleep Quality Index (PSQI) Sleep Quality Mean Score

    Item 9 from the Pittsburgh Sleep Quality Index (PSQI) was used to measure sleep quality. All participants completed this measure at PRO time points T1 and T4 that covered 30 days prior to assessment. "During the past month, how would you rate your sleep quality overall?" The response set ranged from a minimum of 0 (Very Good) to a maximum of 3 (Very Bad). Higher scores indicated worse sleep quality.

    Time frame: Baseline (T1), Week 14 (T4)

  9. Percentage of Overall Medication Adherence

    Medication Adherence Visual Analog Scales (VAS) was used to evaluate medication adherence for up to five daily medications for multiple comorbidities in the past 7 days in participants who were prescribed medications at baseline. Participants reported the average adherence over the course of 7 days for each medication on a scale from 0% to 100% adherence for each medication. The average percent adherence was created for all medications for each patient and could range from 0% to 100%. Overall medication adherence adherence was assessed at T1 and T4.

    Time frame: Baseline (T1), Week 14 (T4)

  10. Alcohol Total Mean Score

    Three items from the Substance Abuse and Mental Illness Symptoms Screener (SAMISS) Survey was administered at baseline (T1) and Week 14 (T4) to evaluate self-reported alcohol use in all participants. The three items evaluated frequency, amount of alcohol consumption, and binge drinking. Individual scores could range from 0 to 4, with higher scores indicating higher consumption.

    Time frame: Baseline (T1), Week 14 (T4)

  11. Percentage of Participants Who Improved Fruit Consumption by One or More Categories

    Behavioral Risk Factor Surveillance System (BRFSS) items assessed fruit intake as a health behavior - "Over the past 12 months, how often did you eat fruits?" Original 8-point response scale ranged from "1 time per month" to "2 or more times/day." Recoded 8 categories into 4 categories, ranging from "Daily consumption" to "Less than weekly". The percentage shown is the number of participants who improved by 1 or more categories based on the 4 category levels from T1 to T4.

    Time frame: Baseline (T1) to Week 14 (T4)

  12. Percentage of Participants Who Improved Vegetable Consumption by One or More Categories

    Behavioral Risk Factor Surveillance System (BRFSS) items measured vegetable intake as a health behavior - "Over the past 12 months, how often did you eat vegetables?" Original 8-point response scale ranged from "1 time per month" to "2 or more times/day." Recoded 8 categories into 4 categories, ranging from "Daily consumption" to "Less than weekly". The percentage is the number of participants who improved by 1 or more categories on the 4 category levels from T1 to T4.

    Time frame: Baseline (T1) to Week 14 (T4)

  13. Percentage of Participants Who Complete Moderate Activity for at Least 10 Minutes at a Time

    Behavioral Risk Factor Surveillance System (BRFSS) items measured moderate activity as a health behavior in all participants at T1 (baseline) and T4 (week 14) and will cover 30 days prior to assessment. BRFSS item asks "Do you do moderate activity for at least 10 minutes at a time"? Response options: Yes/No. Percentage is participants who indicate "Yes" to doing moderate activity for at least 10 minutes at a time

    Time frame: Baseline (T1), Week 14 (T4)

  14. Mean Number of Minutes of Moderate Activity Per Week

    Behavioral Risk Factor Surveillance System (BRFSS) items measured moderate activity as a health behavior by combining two BRFSS items: "If yes, how many days per week do you do these moderate activities for at least 10 minutes at a time" and "If yes, how much total time per day do you spend doing these activities?" Total number of minutes of moderate activity per week calculated as number of days x number of minutes.

    Time frame: Baseline (T1) , Week 14 (T4)

  15. Percentage of Participants Who Complete Vigorous Activity for at Least 10 Minutes at a Time

    Behavioral Risk Factor Surveillance System (BRFSS) items measured vigorous activity as a health behavior - BRFSS Item "Do you do vigorous activity for at least 10 minutes at a time?" Response option: Yes/No. Percentage is participants who indicate "Yes" to doing vigorous activity for at least 10 minutes at a time

    Time frame: Baseline (T1), Week 14 (T4)

  16. Mean Number of Minutes of Vigorous Activity Per Week

    Behavioral Risk Factor Surveillance System (BRFSS) items measured vigorous activity as a health behavior by combining two BRFSS items: "If yes, How many days per week do you do these vigorous activities for at least 10 minutes at a time" and "If yes, how much total time per day do you spend doing these activities?" Total number of minutes of vigorous activity per week calculated as number of days x number of minutes.

    Time frame: Baseline (T1), Week 14 (T4)

  17. Mean Time Spent Sitting on the Weekdays

    Behavioral Risk Factor Surveillance System (BRFSS) items measured sedentarism as a health behavior - BRFSS item "What is the total number of hours you spend siting on a weekday?" The mean can range from a minimum of 0 to maximum of 24 hours. Average numbers of hours spent sitting on the weekday was assessed at T1 to T4.

    Time frame: Baseline (T1), Week 14 (T4)

  18. Mean Time Spent Sitting on the Weekends

    Behavioral Risk Factor Surveillance System (BRFSS) items measured sedentarism as a health behavior - BRFSS Item "What is the total number of hours you spend sitting on a weekend day?" Mean ranges from a minimum of 0 to maximum of 24 hours. Average numbers of hours spent sitting on the weekends assessed at T1 and T4.

    Time frame: Baseline (T1), Week 14 (T4)

  19. Percentage of Participants Who Reduced Regular Soda Intake by One or More Categories

    Behavioral Risk Factor Surveillance System (BRFSS) items measured soda intake as a health behavior - BRFSS item "During the past 30 days, how often did you drink regular soda or pop that contains sugar? Do not include diet soda or diet pop." Original 9-point response scale ranged from "Never" to "6 more more per day." Recoded 9 categories into 5 categories, ranging from "Never" to Daily." The percentage is the number of participants who improved (consumed less) by 1 or more categories on the 5 category levels from T1 to T4.

    Time frame: Baseline (T1) to Week 14 (T4)

  20. Percentage of Participants Who Reduced Diet Soda Intake by One or More Categories

    Behavioral Risk Factor Surveillance System (BRFSS) items measured diet soda intake as a health behavior - BRFSS item "During the past 30 days, how often did you drink diet soda or diet pop that contains an artificial sweeter?" Original 9-point response scale ranged from "Never" to "6 or more per day." Recoded 9 categories into 5, ranging from "Never" to Daily." The percentage is the number of patients who improved (consumed less) by 1 or more categories on the 5 recoded category level from T1 to T4.

    Time frame: Baseline (T1) to Week 14 (T4)

  21. Percentage of Participants Who Reduced Fruit Juice Intake by One or More Categories

    Behavioral Risk Factor Surveillance System (BRFSS) items measured fruit juice intake as a health behavior - BRFSS item "During the past month, how many times per day, week or month did you drink 100% pure fruit juices? Original 9-point response scale ranged from "Never" to "6 or more per day." Recoded 9 categories into 5, ranging from "Never" to Daily." The percentage is the number of participants who improved (consumed less) by 1 or more categories on the 5 recoded category levels from T1 to T4.

    Time frame: Baseline (T1) to Week 14 (T4)

  22. Percentage of Participants Who Reduced Meals From Fast Food Restaurants by One or More Categories

    Behavioral Risk Factor Surveillance System (BRFSS) items measured fast food intake as a health behavior - BRFSS item "In a typical week, how many of your own meals come from fast food restaurants?" Original 9-point response scale ranged from "Never" to "6 or more per day." Recoded 9 categories into 5, ranging from "Never" to Daily." The percentage is the number of participants who improved (reduced) by 1 or more categories on the 5 recoded category levels from T1 to T4.

    Time frame: Baseline (T1) to Week 14 (T4)

  23. Percentage of Participants Who Increased Dinners Prepared at Home by 1 or More Days

    Behavioral Risk Factor Surveillance System (BRFSS) items measured food prepared at home as a health behavior - BRFSS item "On how many days per week do you usually eat a dinner that is prepared at home?" 7-point response scale ranged from 0 to 7 days. The percentage is the number of patients who improved (increased) by 1 or more days from T1 to T4.

    Time frame: Baseline (T1) to Week 14 (T4)

  24. Change in Weight (Lbs)

    Change in weight (lbs) among those who had pre-intervention BMI \> 24.9 (obese and above) from T1 to T4.

    Time frame: Baseline (T1) to Week 14 (T4)

  25. Change in Percent Weight Change

    Change in percent weight (lbs) among those who had pre-intervention BMI \> 24.9 (obese and above) from T1 to T4.

    Time frame: Baseline (T1) to Week 14 (T4)

  26. Change in Body Mass Index (BMI)

    Change in Body Mass Index (BMI) among those who had pre-intervention BMI \> 24.9 (obese and above) from T1 to T4.

    Time frame: Baseline (T1) to Week 14 (T4)

  27. Prescription Drug Misuse Total Mean Score

    Surveys administered at baseline (T1) and Week 14 (T4) evaluated self-reported prescription drug misuse in all participants. One item from the Substance Abuse and Mental Illness Symptoms Screener (SAMISS) Survey evaluated misuse of prescription drugs in the last year. The response options ranged from a minimum of 0="Never" to a maximum of 4="Daily/Almost Daily". Higher scores indicate higher consumption.

    Time frame: Baseline (T1), Week 14 (T4)

  28. Non-prescription Street Drug Use Total Mean Score

    Surveys administered at baseline (T1) and Week 14 (T4) evaluated self-reported non-prescription street drug use in all participants. One item from the Substance Abuse and Mental Illness Symptoms Screener (SAMISS) Survey evaluated non-prescription street drug use in the last year. The response options ranged from a minimum of 0="Never" to a maximum of 4="Daily/Almost Daily". Higher scores indicate higher consumption.

    Time frame: Baseline (T1), Week 14 (T4)

  29. Pittsburgh Sleep Quality Index (PSQI) Sleep Efficiency Composite Mean Score

    Items 1, 3 and 4 from the Pittsburgh Sleep Quality Index (PSQI) were used to create a Sleep Efficiency composite score. All participants completed this measure at T1 and T4 that covered 30 days prior to assessment. The sleep efficiency score = (# hours slept/# hours in bed) X 100% .The sleep efficiency composite score ranged from: 0 = \>85% efficiency, 1 = 75-84% efficiency, 2= 65-74% efficiency, and 3= \<65%. Lower scores indicate better sleep efficiency.

    Time frame: Baseline (T1), Week 14 (T4)

  30. Healthy Sleep Behaviors Mean Score

    One item "In the last month, how often did you engage in healthy sleep behaviors before bedtime?" evaluated healthy sleep behaviors. All participants completed this measure at T1 and T4. The response set ranged from 0 (not at all) to 4 (almost every night). Higher scores indicated better sleep behaviors.

    Time frame: Baseline (T1), Week 14 (T4)

Other outcomes

  1. Salivary Cortisol Area Under the Curve With Respect to Ground (AUC-G)

    Participants in both conditions collected saliva samples at Baseline (T1) and Week 14 (T4). Participants were instructed to collect four saliva samples at each timepoint; 1) immediately upon awakening 2) 30 minutes after awakening 3) late afternoon 4) before bedtime. The mean AUC-G was then obtained at T1 and T4. Mean AUC-G scores could range from 0.195 to 2.29.

    Time frame: Baseline (T1), Week 14 (T4)

  2. Participant Satisfaction With VC-CBCS Telehealth Session Mean Score

    After intervention week 1 and week 14, participants in the VC-CBCS intervention completed a 15-item acceptability/satisfaction survey about their satisfaction with using telehealth sessions. Items were scored on a scale from 1= strongly disagree to 5=strongly agree. The average Total Telehealth Satisfaction score from week 1 and week 14 was created, which ranged from 1 to 5 with higher scores indicating greater satisfaction. A previously developed Telehealth Patient Satisfaction Questionnaire was modified for this study.

    Time frame: Baseline (T1) to Week 14 (T4)

07

Results

Posted Feb 4, 2022

Participant flow

Participant flow — Overall Study
MilestoneVC-CBCS InterventionStandard of Care (SC)
Started248
Randomized to wave 152
Randomized to wave 272
Randomized to wave 362
Randomized to wave 462
Total randomized248
Actually received treatment218
Completed198
Not completed50

Outcome measures

PrimaryPercentage of Patients Consented Versus Approached

One feasibility measure was to evaluate the percentage of patients consented compared to those approached for participation in the study.

Time frame:
Six Months
Reported as:
Number · percentage of participants
Percentage of Patients Consented Versus Approached
percentage of participantsAll Patients
Percentage of Patients Consented Versus Approached74
PrimaryPercentage of Participants Consented Versus Randomized

One feasibility measure was to evaluate the percentage of participants randomized for the study compared to those consented.

Time frame:
Six Months
Reported as:
Number · percentage of participants
Percentage of Participants Consented Versus Randomized
percentage of participantsAll Participants
Percentage of Participants Consented Versus Randomized82
PrimaryPercentage of Standard of Care Condition Participants Retained vs Enrolled

Percentage of standard of care condition participants retained in the study compared to those enrolled. Retention is defined as participants who submitted PRO assessments up through T4 (end of study).

Time frame:
Six Months
Reported as:
Number · percentage of participants
Percentage of Standard of Care Condition Participants Retained vs Enrolled
percentage of participantsStandard of Care (SC)
Percentage of Standard of Care Condition Participants Retained vs Enrolled100
PrimaryPercentage of VC-CBCS Intervention Condition Participants Retained vs Enrolled

Percentage of VC-CBCS Intervention participants retained in the study compared to those enrolled. Retention is defined as participants who completed at least 3 intervention sessions.

Time frame:
Six Months
Reported as:
Number · percentage of participants
Percentage of VC-CBCS Intervention Condition Participants Retained vs Enrolled
percentage of participantsVC-CBCS Intervention
Percentage of VC-CBCS Intervention Condition Participants Retained vs Enrolled79.2
PrimaryPercentage of Surveys Completed by Participants Who Completed the Study

Percentage of surveys over time completed by participants who completed the study. Surveys included 12 patient-reported primary and secondary outcome measures. Completion was defined as submission of each of the 12 surveys at Time 1 (T1) through Time 4 (T4).

Time frame:
Baseline (T1) to Week 14 (T4)
Reported as:
Number · percentage of surveys completed
Percentage of Surveys Completed by Participants Who Completed the Study
percentage of surveys completedAll Enrolled Participants
Percentage of Surveys Completed by Participants Who Completed the Study99.4
PrimaryGlobal Health Status Physical Health Mean T-Score

The Patient Reported Outcome Measurement Information System (PROMIS) Global Health Status measure is a 10-item short form that was used to measure an individual's physical, mental, and social health. Item responses range from 5 = None to 1 = Very Severe. The adult PROMIS Global Health measure produces two scores: Physical Health and Mental Health. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 16.2 to 67.7. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation better (more healthy) than the general population.

Time frame:
Baseline (T1), Week 14 (T4)
Reported as:
Mean · T-score
Global Health Status Physical Health Mean T-Score
T-scoreVC-CBCS InterventionStandard of Care (SC)
Baseline (T1)45.7 (27.3 to 64.1)41.8 (27.2 to 56.4)
Week 14 (T4)46.0 (31.7 to 60.3)48 (31.5 to 64.5)
PrimaryGlobal Health Status Mental Health Mean T-Score

The PROMIS Global Health Status measure is a 10-item short form that was used to measure an individual's physical, mental, and social health. Item responses range from 5 = None to 1 = Very Severe. The adult PROMIS Global Health measure produces two scores: Physical Health and Mental Health. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 21.2 to 67.7. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation better (more healthy) than the general population.

Time frame:
Baseline (T1), Week 14 (T4)
Reported as:
Mean · T-score
Global Health Status Mental Health Mean T-Score
T-scoreVC-CBCS InterventionStandard of Care (SC)
Baseline (T1)46.7 (27.7 to 65.7)41.9 (26.0 to 57.8)
Week 14 (T4)49.3 (34.6 to 64.0)45.9 (31.0 to 60.8)
PrimaryDepression Mean T-score

The PROMIS Depression measure is an 8-item short form that was used to measure patient-reported depression. Item responses range from 1 = Never to 5 = Always. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 41.0 to 79.4. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation more (more Depression) than the general population.

Time frame:
Baseline (T1), Week 14 (T4)
Reported as:
Mean · T-score
Depression Mean T-score
T-scoreVC-CBCS InterventionStandard of Care (SC)
Baseline (T1)52.3 (35.2 to 69.4)51.6 (31.0 to 72.2)
Week 14 (T4)48.6 (35.1 to 62.1)49.0 (33.0 to 65.0)
PrimaryAnger Mean T-score

The PROMIS Anger measure is a 5-item short form that was used to measure patient-reported anger. Item responses range from 1 = Never to 5 = Always. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 32.9 to 82.9. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation more Anger and T-score=40 is 1 standard deviation less Anger than the general population.

Time frame:
Baseline (T1), Week 14 (T4)
Reported as:
Mean · T-score
Anger Mean T-score
T-scoreVC-CBCS InterventionStandard of Care (SC)
Baseline (T1)51.0 (31.8 to 70.2)52.3 (31.3 to 73.3)
Week 14 (T4)46.5 (30.8 to 62.2)46.9 (26.8 to 67.0)
PrimaryAnxiety Mean T-score

The PROMIS Anxiety measure is a 4-item short form that was used to measure patient-reported anxiety. Item responses range from 1 = Never to 5 = Always. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 40.3 to 81.6. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation more Anxiety and T-score=40 is 1 standard deviation less Anxiety than the general population. The Anxiety T-score can range from 40.3 - 81.6.

Time frame:
Baseline (T1), Week 14 (T4)
Reported as:
Mean · T-score
Anxiety Mean T-score
T-scoreVC-CBCS InterventionStandard of Care (SC)
Baseline (T1)52.7 (33.9 to 71.5)57.7 (42.0 to 73.4)
Week 14 (T4)50.4 (34.7 to 66.1)51.2 (34.6 to 67.8)
PrimaryFatigue Mean T-score

The PROMIS Fatigue measure is a 7-item short form that was used to measure patient-reported fatigue. Item responses range from 1 = Never to 5 = Always. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 29.4 to 83.2. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation more Fatigue and T-score=40 is 1 standard deviation less Fatigue than the general population.

Time frame:
Baseline (T1), Week 14 (T4)
Reported as:
Mean · T-score
Fatigue Mean T-score
T-scoreVC-CBCS InterventionStandard of Care (SC)
Baseline (T1)51.9 (30.4 to 73.4)50.4 (30.5 to 70.3)
Week 14 (T4)48.6 (29.9 to 67.3)46.6 (26.6 to 66.6)
PrimarySleep Disturbance Mean T-score

The PROMIS Sleep Disturbance measure is an 8-item short form that was used to measure patient-reported sleep disturbance. Item responses range from 1 = Never to 5 = Always. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 32.0 to 73.3. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation more Sleep Disturbance and T-score=40 is 1 standard deviation less Sleep Disturbance than the general population.

Time frame:
Baseline (T1), Week 14 (T4)
Reported as:
Mean · T-score
Sleep Disturbance Mean T-score
T-scoreVC-CBCS InterventionStandard of Care (SC)
Baseline (T1)52.0 (33.4 to 70.6)50.8 (37.6 to 64.0)
Week 14 (T4)50.0 (36.6 to 63.4)46.0 (26.6 to 65.4)
PrimaryPain Interference Mean T-score

The PROMIS Pain Interference measure is an 8-item short form that was used to measure patient-reported pain interference. Item responses range from 1 = Never to 5 = Always. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 41.6 to 75.6. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation more Pain Interference and T-score=40 is 1 standard deviation less Pain Interference than the general population.

Time frame:
Baseline (T1), Week 14 (T4)
Reported as:
Mean · T-score
Pain Interference Mean T-score
T-scoreVC-CBCS InterventionStandard of Care (SC)
Baseline (T1)53.5 (37.0 to 70.0)55.8 (39.9 to 71.7)
Week 14 (T4)52.0 (34.6 to 69.4)54.6 (37.5 to 71.7)
SecondaryPerceived Stress Mean Score

The Perceived Stress Scale (PSS) is a widely used survey to measure stress perception. The scale includes 10 items, rated using a 5-point scale, from 0 (never) to 4 (very often) where patients report the frequency of stress symptoms in the past month. Items are summed with a minimum and maximum ranging from 0 to 40. Higher PSS scores reflect higher subjective stress.

Time frame:
Baseline (T1), Week 14 (T4)
Reported as:
Mean · score on a scale
Perceived Stress Mean Score
score on a scaleVC-CBCS InterventionStandard of Care (SC)
Baseline (T1)24.2 (20.8 to 27.7)23.9 (18.9 to 28.9)
Week 14 (T4)20.6 (17.9 to 23.4)21.8 (16.1 to 27.4)
SecondaryCoping Skills Confidence Mean Score

The Measure of Current Status (MOCS)-Part A measured participant confidence in performing multiple skills including stress awareness, relaxation, assertiveness, and coping skills. The scale contains 13 items rated on a scale from 0 = I cannot do this at all to 4 = I can do this extremely well. A Total Coping Skills score is created by taking the average of the 13 items. The Total Coping Skill score can range from a minimum of 0 to a maximum of 4.

Time frame:
Baseline (T1), Week 14 (T4)
Reported as:
Mean · score on a scale
Coping Skills Confidence Mean Score
score on a scaleVC-CBCS InterventionStandard of Care (SC)
Baseline (T1)2.18 (1.8 to 2.6)2.16 (1.7 to 2.6)
Week 14 (T4)2.74 (2.4 to 3.1)2.38 (1.9 to 2.9)
SecondaryParticipant Satisfaction With VC-CBCS Intervention Mean Score

After each VC-CBCS intervention session, participants completed a 14-item acceptability/satisfaction survey about their impressions with the current intervention session. Items are scored on a scale from 1= not at all to 5=extremely useful. Data across all VC-CBCS participants and all intervention sessions were averaged into a Total Patient Satisfaction score that could range from a minimum of 1 to a maximum of 5 with higher scores indicating greater satisfaction.

Time frame:
Baseline (T1) to Week 14 (T4)
Reported as:
Mean · score on a scale
Participant Satisfaction With VC-CBCS Intervention Mean Score
score on a scaleVC-CBCS Intervention
Participant Satisfaction With VC-CBCS Intervention Mean Score4.23 ± 0.5
SecondaryAspartate Aminotransferase (AST) Mean Score for Females

Liver enzyme level (AST U/L). Reference range for females is 14-38 U/L. Numbers higher than these reference ranges are considered in the abnormal range and can suggest liver damage or inflammation. These comparisons were only made for participants who had already achieved viral cure at baseline and who were not on medical treatment for chronic hepatitis C at baseline.

Time frame:
Baseline (T1), Week 14 (T4)
Reported as:
Mean · U/L
Aspartate Aminotransferase (AST) Mean Score for Females
U/LVC-CBCS InterventionStandard of Care (SC)
Baseline (T1)28.0 ± 8.9123.0 ± 0.0
Week 14 (T4)31.0 ± 8.89—
SecondaryAspartate Aminotransferase (AST) Mean Score for Males

Liver enzyme level (AST U/L). Reference range for males is 19-55 U/L. Numbers higher than these reference ranges are considered in the abnormal range and can suggest liver damage or inflammation. These comparisons were only made for participants who had already achieved viral cure at baseline and who were not on Hepatitis C Virus (HCV) treatment at baseline.

Time frame:
Baseline (T1), Week 14 (T4)
Reported as:
Mean · U/L
Aspartate Aminotransferase (AST) Mean Score for Males
U/LVC-CBCS InterventionStandard of Care (SC)
Baseline (T1)34.7 ± 11.236.5 ± 17.3
Week 14 (T4)30.0 ± 8.3945.3 ± 31.8
SecondaryAlanine Aminotransferase (ALT) Mean Score for Females

Liver enzyme level (ALT U/L). Reference range for females is \<35 U/L. Numbers higher than these reference ranges are considered in the abnormal range and can suggest liver damage or inflammation. These comparisons were only made for participants who had already achieved viral cure at baseline and who were not on HCV treatment at baseline.

Time frame:
Baseline (T1), Week 14 (T4)
Reported as:
Mean · U/L
Alanine Aminotransferase (ALT) Mean Score for Females
U/LVC-CBCS InterventionStandard of Care (SC)
Baseline (T1)22.0 ± 13.013.0 ± 0.0
Week 14 (T4)28.3 ± 20.0—
SecondaryAlanine Aminotransferase (ALT) Mean Score for Males

Liver enzyme level (ALT U/L). Reference range for males is \<50 U/L. Numbers higher than these reference ranges are considered in the abnormal range and can suggest liver damage or inflammation. These comparisons were only made for participants who had already achieved viral cure at baseline and who were not on HCV treatment at baseline.

Time frame:
Baseline (T1), Week 14 (T4)
Reported as:
Mean · U/L
Alanine Aminotransferase (ALT) Mean Score for Males
U/LVC-CBCS InterventionStandard of Care (SC)
Baseline (T1)34.6 ± 23.033.0 ± 10.3
Week 14 (T4)36.9 ± 24.128.0 ± 12.5
SecondaryPittsburgh Sleep Quality Index (PSQI) Sleep Quality Mean Score

Item 9 from the Pittsburgh Sleep Quality Index (PSQI) was used to measure sleep quality. All participants completed this measure at PRO time points T1 and T4 that covered 30 days prior to assessment. "During the past month, how would you rate your sleep quality overall?" The response set ranged from a minimum of 0 (Very Good) to a maximum of 3 (Very Bad). Higher scores indicated worse sleep quality.

Time frame:
Baseline (T1), Week 14 (T4)
Reported as:
Mean · score on a scale
Pittsburgh Sleep Quality Index (PSQI) Sleep Quality Mean Score
score on a scaleVC-CBCS InterventionStandard of Care (SC)
Baseline (T1)1.32 ± 0.821.13 ± 0.64
Week 14 (T4)1.05 ± 0.520.71 ± 0.76
SecondaryPercentage of Overall Medication Adherence

Medication Adherence Visual Analog Scales (VAS) was used to evaluate medication adherence for up to five daily medications for multiple comorbidities in the past 7 days in participants who were prescribed medications at baseline. Participants reported the average adherence over the course of 7 days for each medication on a scale from 0% to 100% adherence for each medication. The average percent adherence was created for all medications for each patient and could range from 0% to 100%. Overall medication adherence adherence was assessed at T1 and T4.

Time frame:
Baseline (T1), Week 14 (T4)
Reported as:
Number · percentage of medication adherence
Percentage of Overall Medication Adherence
percentage of medication adherenceVC-CBCS InterventionStandard of Care (SC)
Baseline (T1)85.2 (73.9 to 96.5)96.9 (94.7 to 99.1)
Week 14 (T4)92.8 (85.4 to 100.3)89.8 (72.6 to 106.9)
SecondaryAlcohol Total Mean Score

Three items from the Substance Abuse and Mental Illness Symptoms Screener (SAMISS) Survey was administered at baseline (T1) and Week 14 (T4) to evaluate self-reported alcohol use in all participants. The three items evaluated frequency, amount of alcohol consumption, and binge drinking. Individual scores could range from 0 to 4, with higher scores indicating higher consumption.

Time frame:
Baseline (T1), Week 14 (T4)
Reported as:
Mean · score on a scale
Alcohol Total Mean Score
score on a scaleVC-CBCS InterventionStandard of Care (SC)
Baseline (T1)1.39 ± 2.430.13 ± 0.35
Week 14 (T4)0.95 ± 2.270.25 ± 0.71
SecondaryPercentage of Participants Who Improved Fruit Consumption by One or More Categories

Behavioral Risk Factor Surveillance System (BRFSS) items assessed fruit intake as a health behavior - "Over the past 12 months, how often did you eat fruits?" Original 8-point response scale ranged from "1 time per month" to "2 or more times/day." Recoded 8 categories into 4 categories, ranging from "Daily consumption" to "Less than weekly". The percentage shown is the number of participants who improved by 1 or more categories based on the 4 category levels from T1 to T4.

Time frame:
Baseline (T1) to Week 14 (T4)
Reported as:
Number · percentage of patients
Percentage of Participants Who Improved Fruit Consumption by One or More Categories
percentage of patientsVC-CBCS InterventionStandard of Care (SC)
Percentage of Participants Who Improved Fruit Consumption by One or More Categories47.043.0
SecondaryPercentage of Participants Who Improved Vegetable Consumption by One or More Categories

Behavioral Risk Factor Surveillance System (BRFSS) items measured vegetable intake as a health behavior - "Over the past 12 months, how often did you eat vegetables?" Original 8-point response scale ranged from "1 time per month" to "2 or more times/day." Recoded 8 categories into 4 categories, ranging from "Daily consumption" to "Less than weekly". The percentage is the number of participants who improved by 1 or more categories on the 4 category levels from T1 to T4.

Time frame:
Baseline (T1) to Week 14 (T4)
Reported as:
Number · percentage of participants
Percentage of Participants Who Improved Vegetable Consumption by One or More Categories
percentage of participantsVC-CBCS InterventionStandard of Care (SC)
Percentage of Participants Who Improved Vegetable Consumption by One or More Categories1614
SecondaryPercentage of Participants Who Complete Moderate Activity for at Least 10 Minutes at a Time

Behavioral Risk Factor Surveillance System (BRFSS) items measured moderate activity as a health behavior in all participants at T1 (baseline) and T4 (week 14) and will cover 30 days prior to assessment. BRFSS item asks "Do you do moderate activity for at least 10 minutes at a time"? Response options: Yes/No. Percentage is participants who indicate "Yes" to doing moderate activity for at least 10 minutes at a time

Time frame:
Baseline (T1), Week 14 (T4)
Reported as:
Number · percentage of participants
Percentage of Participants Who Complete Moderate Activity for at Least 10 Minutes at a Time
percentage of participantsVC-CBCS InterventionStandard of Care (SC)
Baseline (T1)73.750.0
Week 14 (T4)78.987.5
SecondaryMean Number of Minutes of Moderate Activity Per Week

Behavioral Risk Factor Surveillance System (BRFSS) items measured moderate activity as a health behavior by combining two BRFSS items: "If yes, how many days per week do you do these moderate activities for at least 10 minutes at a time" and "If yes, how much total time per day do you spend doing these activities?" Total number of minutes of moderate activity per week calculated as number of days x number of minutes.

Time frame:
Baseline (T1) , Week 14 (T4)
Reported as:
Mean · minutes
Mean Number of Minutes of Moderate Activity Per Week
minutesVC-CBCS InterventionStandard of Care (SC)
Baseline (T1)314 ± 55687.9 ± 120
Week 14 (T4)528 ± 808170 ± 257
SecondaryPercentage of Participants Who Complete Vigorous Activity for at Least 10 Minutes at a Time

Behavioral Risk Factor Surveillance System (BRFSS) items measured vigorous activity as a health behavior - BRFSS Item "Do you do vigorous activity for at least 10 minutes at a time?" Response option: Yes/No. Percentage is participants who indicate "Yes" to doing vigorous activity for at least 10 minutes at a time

Time frame:
Baseline (T1), Week 14 (T4)
Reported as:
Number · percentage of participants
Percentage of Participants Who Complete Vigorous Activity for at Least 10 Minutes at a Time
percentage of participantsVC-CBCS InterventionStandard of Care (SC)
Baseline (T1)42.150.0
Week 14 (T4)47.425.0
SecondaryMean Number of Minutes of Vigorous Activity Per Week

Behavioral Risk Factor Surveillance System (BRFSS) items measured vigorous activity as a health behavior by combining two BRFSS items: "If yes, How many days per week do you do these vigorous activities for at least 10 minutes at a time" and "If yes, how much total time per day do you spend doing these activities?" Total number of minutes of vigorous activity per week calculated as number of days x number of minutes.

Time frame:
Baseline (T1), Week 14 (T4)
Reported as:
Mean · total minutes in a week
Mean Number of Minutes of Vigorous Activity Per Week
total minutes in a weekVC-CBCS InterventionStandard of Care (SC)
Baseline (T1)241 ± 45755.7 ± 74.4
Week 14 (T4)235 ± 51317.1 ± 34.0
SecondaryMean Time Spent Sitting on the Weekdays

Behavioral Risk Factor Surveillance System (BRFSS) items measured sedentarism as a health behavior - BRFSS item "What is the total number of hours you spend siting on a weekday?" The mean can range from a minimum of 0 to maximum of 24 hours. Average numbers of hours spent sitting on the weekday was assessed at T1 to T4.

Time frame:
Baseline (T1), Week 14 (T4)
Reported as:
Mean · hours
Mean Time Spent Sitting on the Weekdays
hoursVC-CBCS InterventionStandard of Care (SC)
Baseline (T1)8.95 ± 3.446.57 ± 4.08
Week 14 (T4)7.0 ± 2.287.0 ± 2.31
SecondaryMean Time Spent Sitting on the Weekends

Behavioral Risk Factor Surveillance System (BRFSS) items measured sedentarism as a health behavior - BRFSS Item "What is the total number of hours you spend sitting on a weekend day?" Mean ranges from a minimum of 0 to maximum of 24 hours. Average numbers of hours spent sitting on the weekends assessed at T1 and T4.

Time frame:
Baseline (T1), Week 14 (T4)
Reported as:
Mean · hours
Mean Time Spent Sitting on the Weekends
hoursVC-CBCS InterventionStandard of Care (SC)
Baseline (T1)7.68 ± 3.536.0 ± 3.66
Week 14 (T4)4.22 ± 2.266.43 ± 3.10
SecondaryPercentage of Participants Who Reduced Regular Soda Intake by One or More Categories

Behavioral Risk Factor Surveillance System (BRFSS) items measured soda intake as a health behavior - BRFSS item "During the past 30 days, how often did you drink regular soda or pop that contains sugar? Do not include diet soda or diet pop." Original 9-point response scale ranged from "Never" to "6 more more per day." Recoded 9 categories into 5 categories, ranging from "Never" to Daily." The percentage is the number of participants who improved (consumed less) by 1 or more categories on the 5 category levels from T1 to T4.

Time frame:
Baseline (T1) to Week 14 (T4)
Reported as:
Number · percentage of participants
Percentage of Participants Who Reduced Regular Soda Intake by One or More Categories
percentage of participantsVC-CBCS InterventionStandard of Care (SC)
Percentage of Participants Who Reduced Regular Soda Intake by One or More Categories3514
SecondaryPercentage of Participants Who Reduced Diet Soda Intake by One or More Categories

Behavioral Risk Factor Surveillance System (BRFSS) items measured diet soda intake as a health behavior - BRFSS item "During the past 30 days, how often did you drink diet soda or diet pop that contains an artificial sweeter?" Original 9-point response scale ranged from "Never" to "6 or more per day." Recoded 9 categories into 5, ranging from "Never" to Daily." The percentage is the number of patients who improved (consumed less) by 1 or more categories on the 5 recoded category level from T1 to T4.

Time frame:
Baseline (T1) to Week 14 (T4)
Reported as:
Number · percentage of participants
Percentage of Participants Who Reduced Diet Soda Intake by One or More Categories
percentage of participantsVC-CBCS InterventionStandard of Care (SC)
Percentage of Participants Who Reduced Diet Soda Intake by One or More Categories517
SecondaryPercentage of Participants Who Reduced Fruit Juice Intake by One or More Categories

Behavioral Risk Factor Surveillance System (BRFSS) items measured fruit juice intake as a health behavior - BRFSS item "During the past month, how many times per day, week or month did you drink 100% pure fruit juices? Original 9-point response scale ranged from "Never" to "6 or more per day." Recoded 9 categories into 5, ranging from "Never" to Daily." The percentage is the number of participants who improved (consumed less) by 1 or more categories on the 5 recoded category levels from T1 to T4.

Time frame:
Baseline (T1) to Week 14 (T4)
Reported as:
Number · percentage of participants
Percentage of Participants Who Reduced Fruit Juice Intake by One or More Categories
percentage of participantsVC-CBCS InterventionStandard of Care (SC)
Percentage of Participants Who Reduced Fruit Juice Intake by One or More Categories1629
SecondaryPercentage of Participants Who Reduced Meals From Fast Food Restaurants by One or More Categories

Behavioral Risk Factor Surveillance System (BRFSS) items measured fast food intake as a health behavior - BRFSS item "In a typical week, how many of your own meals come from fast food restaurants?" Original 9-point response scale ranged from "Never" to "6 or more per day." Recoded 9 categories into 5, ranging from "Never" to Daily." The percentage is the number of participants who improved (reduced) by 1 or more categories on the 5 recoded category levels from T1 to T4.

Time frame:
Baseline (T1) to Week 14 (T4)
Reported as:
Number · percentage of participants
Percentage of Participants Who Reduced Meals From Fast Food Restaurants by One or More Categories
percentage of participantsVC-CBCS InterventionStandard of Care (SC)
Percentage of Participants Who Reduced Meals From Fast Food Restaurants by One or More Categories3917
SecondaryPercentage of Participants Who Increased Dinners Prepared at Home by 1 or More Days

Behavioral Risk Factor Surveillance System (BRFSS) items measured food prepared at home as a health behavior - BRFSS item "On how many days per week do you usually eat a dinner that is prepared at home?" 7-point response scale ranged from 0 to 7 days. The percentage is the number of patients who improved (increased) by 1 or more days from T1 to T4.

Time frame:
Baseline (T1) to Week 14 (T4)
Reported as:
Number · percentage of participants
Percentage of Participants Who Increased Dinners Prepared at Home by 1 or More Days
percentage of participantsVC-CBCS InterventionStandard of Care (SC)
Percentage of Participants Who Increased Dinners Prepared at Home by 1 or More Days350
SecondaryChange in Weight (Lbs)

Change in weight (lbs) among those who had pre-intervention BMI \> 24.9 (obese and above) from T1 to T4.

Time frame:
Baseline (T1) to Week 14 (T4)
Reported as:
Mean · pounds
Change in Weight (Lbs)
poundsVC-CBCS InterventionStandard of Care (SC)
Change in Weight (Lbs)-2.67 ± 13.70.0 ± 3.56
SecondaryChange in Percent Weight Change

Change in percent weight (lbs) among those who had pre-intervention BMI \> 24.9 (obese and above) from T1 to T4.

Time frame:
Baseline (T1) to Week 14 (T4)
Reported as:
Mean · percent of weight change
Change in Percent Weight Change
percent of weight changeVC-CBCS InterventionStandard of Care (SC)
Change in Percent Weight Change0.91 ± 5.65-0.23 ± 1.91
SecondaryChange in Body Mass Index (BMI)

Change in Body Mass Index (BMI) among those who had pre-intervention BMI \> 24.9 (obese and above) from T1 to T4.

Time frame:
Baseline (T1) to Week 14 (T4)
Reported as:
Mean · kg/m^2
Change in Body Mass Index (BMI)
kg/m^2VC-CBCS InterventionStandard of Care (SC)
Change in Body Mass Index (BMI)-0.53 ± 2.280.23 ± 0.83
SecondaryPrescription Drug Misuse Total Mean Score

Surveys administered at baseline (T1) and Week 14 (T4) evaluated self-reported prescription drug misuse in all participants. One item from the Substance Abuse and Mental Illness Symptoms Screener (SAMISS) Survey evaluated misuse of prescription drugs in the last year. The response options ranged from a minimum of 0="Never" to a maximum of 4="Daily/Almost Daily". Higher scores indicate higher consumption.

Time frame:
Baseline (T1), Week 14 (T4)
Reported as:
Mean · score on a scale
Prescription Drug Misuse Total Mean Score
score on a scaleVC-CBCS InterventionStandard of Care (SC)
Baseline (T1)0.11 ± 0.320.0 ± 0.0
Week 14 (T4)0.11 ± 0.320.0 ± 0.0
SecondaryNon-prescription Street Drug Use Total Mean Score

Surveys administered at baseline (T1) and Week 14 (T4) evaluated self-reported non-prescription street drug use in all participants. One item from the Substance Abuse and Mental Illness Symptoms Screener (SAMISS) Survey evaluated non-prescription street drug use in the last year. The response options ranged from a minimum of 0="Never" to a maximum of 4="Daily/Almost Daily". Higher scores indicate higher consumption.

Time frame:
Baseline (T1), Week 14 (T4)
Reported as:
Mean · score on a scale
Non-prescription Street Drug Use Total Mean Score
score on a scaleVC-CBCS InterventionStandard of Care (SC)
Baseline (T1)1.37 ± 1.710.88 ± 1.36
Week 14 (T4)0.95 ± 1.470.13 ± 0.35
SecondaryPittsburgh Sleep Quality Index (PSQI) Sleep Efficiency Composite Mean Score

Items 1, 3 and 4 from the Pittsburgh Sleep Quality Index (PSQI) were used to create a Sleep Efficiency composite score. All participants completed this measure at T1 and T4 that covered 30 days prior to assessment. The sleep efficiency score = (# hours slept/# hours in bed) X 100% .The sleep efficiency composite score ranged from: 0 = \>85% efficiency, 1 = 75-84% efficiency, 2= 65-74% efficiency, and 3= \<65%. Lower scores indicate better sleep efficiency.

Time frame:
Baseline (T1), Week 14 (T4)
Reported as:
Mean · score on a scale
Pittsburgh Sleep Quality Index (PSQI) Sleep Efficiency Composite Mean Score
score on a scaleVC-CBCS InterventionStandard of Care (SC)
Baseline (T1)1.05 ± 1.221.38 ± 1.30
Week 14 (T4)1.26 ± 1.370.75 ± 1.04
SecondaryHealthy Sleep Behaviors Mean Score

One item "In the last month, how often did you engage in healthy sleep behaviors before bedtime?" evaluated healthy sleep behaviors. All participants completed this measure at T1 and T4. The response set ranged from 0 (not at all) to 4 (almost every night). Higher scores indicated better sleep behaviors.

Time frame:
Baseline (T1), Week 14 (T4)
Reported as:
Mean · score on a scale
Healthy Sleep Behaviors Mean Score
score on a scaleVC-CBCS InterventionStandard of Care (SC)
Baseline (T1)1.37 ± 1.262.13 ± 0.99
Week 14 (T4)2.42 ± 0.842.17 ± 1.33
Other pre-specifiedSalivary Cortisol Area Under the Curve With Respect to Ground (AUC-G)

Participants in both conditions collected saliva samples at Baseline (T1) and Week 14 (T4). Participants were instructed to collect four saliva samples at each timepoint; 1) immediately upon awakening 2) 30 minutes after awakening 3) late afternoon 4) before bedtime. The mean AUC-G was then obtained at T1 and T4. Mean AUC-G scores could range from 0.195 to 2.29.

Time frame:
Baseline (T1), Week 14 (T4)
Reported as:
Mean · ug/dL
Salivary Cortisol Area Under the Curve With Respect to Ground (AUC-G)
ug/dLVC-CBCS InterventionStandard of Care (SC)
Baseline (T1)1.01 ± 0.541.18 ± 0.65
Week 14 (T4)0.71 ± 0.230.83 ± 0.46
Other pre-specifiedParticipant Satisfaction With VC-CBCS Telehealth Session Mean Score

After intervention week 1 and week 14, participants in the VC-CBCS intervention completed a 15-item acceptability/satisfaction survey about their satisfaction with using telehealth sessions. Items were scored on a scale from 1= strongly disagree to 5=strongly agree. The average Total Telehealth Satisfaction score from week 1 and week 14 was created, which ranged from 1 to 5 with higher scores indicating greater satisfaction. A previously developed Telehealth Patient Satisfaction Questionnaire was modified for this study.

Time frame:
Baseline (T1) to Week 14 (T4)
Reported as:
Mean · score on a scale
Participant Satisfaction With VC-CBCS Telehealth Session Mean Score
score on a scaleVC-CBCS Intervention
Week 13.91 ± 0.68
Week 144.5 ± 0.38

Adverse events

Collected over From the time of first intervention session through the last intervention session, an approximate total of 14 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
VC-CBCS Intervention0/21 (0%)1/21 (4.8%)0/21 (0%)
Standard of Care (SC)0/8 (0%)0/8 (0%)0/8 (0%)
Most frequent serious events
Most frequent serious events
EventVC-CBCS InterventionStandard of Care (SC)
Transient Ischemic Attack (TIA)Vascular disorders1/210/8

Baseline characteristics

Age, Continuous
Age, Continuous(years)VC-CBCS InterventionStandard of Care (SC)Total
Mean56 ± 7.556 ± 11.456 ± 8.5
Sex: Female, Male
Sex: Female, Male(Participants)VC-CBCS InterventionStandard of Care (SC)Total
Female538
Male19524
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)VC-CBCS InterventionStandard of Care (SC)Total
Hispanic or Latino000
Not Hispanic or Latino14519
Unknown or Not Reported10313
Race (NIH/OMB)
Race (NIH/OMB)(Participants)VC-CBCS InterventionStandard of Care (SC)Total
American Indian or Alaska Native202
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American527
White16521
More than one race112
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)VC-CBCS InterventionStandard of Care (SC)Total
United States24832
08

Study locations

1 site
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Nov 16, 2021

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 24, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04198584
Responsible party
Sponsor
First posted
Dec 13, 2019
Start date
Apr 10, 2020
Primary completion
Jan 12, 2021
Completion
Feb 24, 2021
Results posted
Feb 4, 2022
Last update
Oct 24, 2022

Study contacts

Donna M. Evon, PhD
principal investigator · University of North Carolina, Chapel Hill

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion